HMO Fermentation via PanD Gene Deletion to Reduce Pantothenic Acid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for producing human milk oligosaccharides (HMOs) are not feasible for industrial-scale production due to high costs and the need for expensive educts, making it challenging to incorporate HMOs into infant formula at affordable prices.
Innovation Solution
The development of fermentative production processes using metabolically engineered bacterial cells, such as Escherichia coli, which are capable of intracellularly synthesizing HMOs, thereby avoiding the need for expensive educts and allowing for the production of HMOs in sufficiently pure form at economically feasible costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chemical synthesis or in vitro biocatalysis is used to produce HMOs, then HMOs can be produced with high purity, but the production costs become prohibitively expensive for industrial-scale application
Solution Approach 1:
The microbial cell is engineered to synthesize HMOs autonomously using its own metabolic pathways. The cell takes simple carbon sources (glucose, galactose) from the culture medium and converts them into HMOs through endogenous enzymatic reactions, eliminating the need for expensive external educts required in chemical synthesis or in vitro biocatalysis
Solution Approach 2:
The patent replaces complex mechanical/chemical synthesis systems with a biological system. Instead of using expensive chemical reagents and multi-step synthetic protocols, the invention uses a genetically engineered microorganism that naturally performs the synthesis through metabolic pathways, significantly reducing production costs while maintaining high purity
2Ease of manufacture
If conventional microbial fermentation is used for HMO production, then production costs are reduced, but pantothenic acid accumulates in the culture medium requiring additional purification steps
Solution Approach 1:
The patent removes the harmful byproduct (pantothenic acid accumulation) from the system by deleting the panD gene encoding aspartate α-decarboxylase, the enzyme responsible for pantothenic acid synthesis. This genetic modification eliminates the source of the contamination problem while preserving HMO production capability
Solution Approach 2:
The patent converts a harmful metabolic byproduct (pantothenic acid accumulation that complicates purification) into a beneficial outcome by genetically eliminating its production. The deletion of panD gene prevents pantothenic acid synthesis, thereby simplifying downstream purification processes without affecting HMO yield or quality
3Manufacturing precision
If HMOs are produced using expensive educts through chemical synthesis, then high purity HMOs are obtained, but the scalability to industrial production levels is limited
Solution Approach 1:
The engineered microbial cell autonomously produces all necessary precursors and catalyzes the formation of HMOs through its metabolic pathways. The cell utilizes simple, inexpensive carbon sources from the culture medium and converts them into complex HMO structures through endogenous enzymes, enabling scalable production without relying on expensive external educts
Solution Approach 2:
The patent changes the fundamental production parameter from using expensive chemical educts to using simple carbon sources (glucose, galactose) in the culture medium. This parameter change enables industrial-scale fermentation because the substrate is inexpensive, readily available, and supports high cell density cultivation, thereby achieving both high purity and large-scale production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of HMOs in large quantities at reduced costs, making them more viable for use in infant formula, while also ensuring the HMOs are produced in a pure and economically feasible manner.
Implementation Method 1
fermentative production processes using metabolically engineered bacterial cells, such as Escherichia coli, which are capable of intracellularly synthesizing HMOs
Data Source
AI summary
Disclosed are means and methods for the fermentative production of an oligosaccharide of interest by a genetically engineered microbial cell, wherein concomitant biosynthesis of pantothenic acid is reduced or abolished.